Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables

Pathology and Oncology Research

Volumn 17, Issue 4, 2011, Pages 809-817

  Rykala, Jan ^a   Przybylowska, Karolina ^b   Majsterek, Ireneusz ^b   Pasz Walczak, Grazyna ^b   Sygut, Andrzej ^b   Dziki, Adam ^b   Kruk Jeromin, Julia ^a  

^a N Barlicki University Hospital No 1 of Medical University of Lodz   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; Breast cancer; Cancer progression; Multiplex protein assay

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; KERATINOCYTE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PROGESTERONE RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; MICROVASCULATURE; MOLECULAR PATHOLOGY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FIBROBLAST GROWTH FACTOR 7; FIBROBLAST GROWTH FACTORS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-SIS; RIBONUCLEASE, PANCREATIC; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VESICULAR TRANSPORT PROTEINS;

EID: 84855421440     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9387-6     Document Type: Article

References (37)

1. Baeriswyl V, Christofori G (2009) The angiogenic switch in carcinogenesis. Semin Cancer Biol 19(5):329-337
2. Fujita Y, Abe R, Shimizu H (2008) Clinical approaches toward tumor angiogenesis: Past, present and future. Curr Pharm Des 14 (36):3820-3834
3. Poon RT, Fan ST, Wong J (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19 (4):1207-1225 (Pubitemid 32176299)
4. Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis. Cancer Res 64(9):2941-2945
5. Ozalp S, Yalcin OT, Acikalin M, Tanir HM, Oner U, Akkoyunlu A (2003) Microvessel density (MVD) as a prognosticator in endometrial carcinoma. Eur J Gynaecol Oncol 24(3-4):305-308 (Pubitemid 36644620)
6. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R (2002) Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 5(2):123-127 (Pubitemid 34777895)
7. Liang JT, Huang KC, Jeng YM, Lee PH, Lai HS, Hsu HC (2004) Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br J Surg 91(3):355-361
8. Szarvas T, Jäger T, Droste F, Becker M, Kovalszky I, Romics I, Ergün S, Rübben H (2009) Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res 15 (2):193-201
9. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E (2006) Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 16(5):405-411 (Pubitemid 44511220)
10. Balacescu O, Neagoe I, Balacescu L, Crisan N, Feciche B, Tudoran O, Coman I, Irimie A (2008) Angiogenesis serum protein quantification for prostate. Pathology Curr Urol 2:181-187
11. Balsari A, Maier JA, Colnaghi MI, Ménard S (1999) Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. Lab Invest 79(7):897-902 (Pubitemid 29344502)
12. Zhao J, Yan F, Ju H, Tang J, Qin J (2004) Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 204(1):87-95 (Pubitemid 38117197)
13. Duranyildiz D, Camlica H, Soydinc HO, Derin D, Yasasever V (2009) Serum levels of angiogenic factors in early breast cancer remain close to normal. Breast 18(1):26-29
14. Weidner N, Semple JP, Welch ER, Folkman J (1991) Tumor angiogenesis et metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8
15. Vermeulen PB, Gasparini G, Fox SB (1996) Quantification of angiogenesis in solid human tumors: An International Consensus on the methodology and criteria of evaluation. Eur J Cancer 32:2474-2484
16. Kranz A, Mattfeldt T, Waltenberger J (1999) Molecular mediators of tumor angiogenesis: Enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 84(3):293-298 (Pubitemid 29256757)
17. Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG (2008) High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 39(12):1835-1843
18. Kawai H, Li H, Chun P, Avraham S, Avraham HK (2002) Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21(50):7730-7739 (Pubitemid 35398818)
19. Ali SH, O'Donnell AL, Balu D, Pohl MB, Seyler MJ, Mohamed S, Mousa S, Dandona P (2000) Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res 60 (24):7094-7098 (Pubitemid 32059189)
20. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van derWall E (2005) Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46(1):31-36 (Pubitemid 40193695)
21. Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee WK, Cheng SY (2003) Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162(4):1083-1093 (Pubitemid 36350654)
22. Zhu L, Loo WT, Cheng CW, Chow LW (2006) Possible predictive markers related to micro-metastasis in breast cancer patients. Oncol Rep 15(5):1217-1223
23. Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D (1987) Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 325(6101):257-259 (Pubitemid 17049885)
24. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2006) Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch 448(1):68-74 (Pubitemid 43177417)
25. Shi YH, Bingle L, Gong LH, Wang YX, Corke KP, Fang WG (2007) Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. Pathology 39(4):396-400 (Pubitemid 47221464)
26. Sartippour MR, Zhang L, Lu M, Wang HJ, Brooks MN (2005) Nipple fluid basic fibroblast growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 14(12):2995-2998 (Pubitemid 43068837)
27. Würtz SO, Schrohl AS, Mouridsen H, Brünner N (2008) TIMP-1 as a tumor marker in breast cancer-an update. Acta Oncol 47 (4):580-590 (Pubitemid 351878454)
28. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor ofmetalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298(1):29-32
29. Liu XW, Bernardo MM, Fridman R, Kim HR (2003) Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 278(41):40364-40372 (Pubitemid 37248605)
30. Liu H, Chen B, Lilly B (2008) Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1. Angiogenesis 11(3):223-234
31. O'Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone C, Given HF (2002) Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 38:2252-2257 (Pubitemid 35346466)
32. Kostler WJ, Tomek S, Brodowicz T et al (2001) Soluble ICAM-1 in breast cancer: Clinical significance and biological implications. Cancer Immunol Immunother 50:483-490 (Pubitemid 33079345)
33. Kawai Y, Kaidoh M, Yokoyama Y, Sano K, Ohhashi T (2009) Chemokine CCL2 facilitates ICAM-1-mediated interactions of cancer cells and lymphatic endothelial cells in sentinel lymph nodes. Cancer Sci 100(3):419-428
34. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, Era S, Mori M (2006) Angiopoietin 2 expression in invasive ductal carcinoma of the breast: Its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 98(3):261-266 (Pubitemid 44195595)
35. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, Augustin HG (2009) Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 15(4):1384-1392
36. Zhou YZ, Fang XQ, Li H, Diao YT, Yang YF, Zhao DL, Wu K, Li HQ (2007) Role of serum angiopoietin-2 level in screening for esophageal squamous cell cancer and its precursors. Chin Med J (Engl) 120(14):1216-1219 (Pubitemid 47232903)
37. A Randomized Phase III Trial of Paclitaxel With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer: Eastern Cooperative Oncology Group trial E 2100. Abstract 7